Goldfarb, David S. http://orcid.org/0000-0002-9215-1273
Lieske, John C.
Groothoff, Jaap
Schalk, Gesa
Russell, Kerry
Yu, Shuli
Vrhnjak, Blaz
Funding for this research was provided by:
Dicerna Pharmaceuticals, Inc., a Novo Nordisk Company
Article History
Received: 17 February 2023
Accepted: 18 April 2023
First Online: 28 April 2023
Change Date: 5 June 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00240-023-01455-1
Declarations
:
: DSG: Consultant for Dicerna, Inc., a Novo Nordisk Company, Alnylam, Synlogic, Sumitovant, Orfan, BridgeBio/Cantero; Research funding from Dicerna, Inc., a Novo Nordisk Company, Alnylam, Travere; Owner, Moonstone Nutrition; JCL: Consultant for Alnylam, Dicerna Inc., a Novo Nordisk Company, OxThera, BridgeBio/Cantero, Chinook, BioMarin, Synlogic, Novobiome, Oxidien, Federation Bio, Intellia, Precision BioSciences; Research funding from OxThera, Allena, Siemens, Alnylam, Dicerna, Inc, a Novo Nordisk Company, Synlogic, Novobiome, Arkray; JG: Research funding from Dicerna Inc., a Novo Nordisk Company, Alnylam, UniQure; Consultant for Alnylam Eu 2000 CF; Scientific advisor for Alnylam; serves as chair of OxalEurope; GS has nothing to disclose; KR was an employee of Dicerna Inc., a Novo Nordisk Company at the time of the completion of this study; SY is an employee of Dicerna Inc., a Novo Nordisk Company; and BV is an employee of Novo Nordisk.
: This study was conducted in accordance with the provisions of the Declaration of Helsinki, Good Clinical Practice Guidelines of the International Conference on Harmonisation, and all applicable laws and regulations.
: Written informed consent was obtained from all adult participants and the parents or legal guardians of participating children. All children assented as appropriate.